Frontier Biotechnologies Inc. (SHA:688221)

Market Cap	6.88B +107.5%
Revenue (ttm)	392.19M +194.5%
Net Income	3.46M
EPS	0.01
Shares Out	374.58M
PE Ratio	1,986.36
Forward PE	764.14
Dividend	n/a
Ex-Dividend Date	n/a

Volume	11,019,210
Open	17.88
Previous Close	17.64
Day's Range	17.58 - 18.65
52-Week Range	9.53 - 29.98
Beta	0.90
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 28, 2026

About Frontier Biotechnologies

Frontier Biotechnologies Inc., a commercial-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes various medicines that improve patients’ health in China. It offers Aikening, a long-acting HIV fusion inhibitor for the treatment of HIV infection and AIDS. The company’s products under development include small RNA drugs, such as FB7011/FB7013/FB7014 to treat IgA nephropathy, FB7022/FB7021 for dyslipidemia, and FB7012/FB7041/FB7031/FB7032 for various other diseases, including hyperuricemia and gout, tumors, and me...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2002
• Employees: 314
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688221

Financial Performance

In 2025, Frontier Biotechnologies's revenue was 123.39 million, a decrease of -4.70% compared to the previous year's 129.47 million. Losses were -268.05 million, 33.1% more than in 2024.